Annemarie Linda Dreimanis Linares Daly, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Pain Med.
Volume: 15(5)
Date: 05 2014

A transit compartment model unmasks OxyContin's reflective pharmacokinetics from urine measurements in humans.
J Pain Palliat Care Pharmacother.
Volume: 28(2)
Date: 06 2014

. Oxycodone recycling: a novel hypothesis of opioid tolerance development in humans.
Med Hypotheses.
Volume: 83(3)
Date: 09 2014

CYP2D6 phenotype-specific codeine population pharmacokinetics.
J Pain Palliat Care Pharmacother.
Volume: 29(1)
Date: 03 2015

Organ-specific microcirculatory mass transport of oxycodone in humans: clinical implications for therapeutic use.
Clin J Pain.
Volume: 31(3)
Date: 03 2015

Integrating Clinical Pharmacokinetics, Pharmacogenetics, and Quantitative Cytochrome P450 Polymorphic Gene Drug-Drug Interactions (DDIs).
Pain Physician
Volume: 18(3)
Date: 05 2015

In silico ordinary differential equation/partial differential equation hemodialysis model estimates methadone removal during dialysis.
J Pain Res.
Volume: 8
Date: 07 2015

Methadone Recycling Sustains Drug Reservoir in Tissue.
J Pain Palliat Care Pharmacother.
Volume: 29(3)
Date: 09 2015

Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Clin J Pain.
Volume: 31(12)
Date: 12 2015